Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $17.50 price target on the stock.
A number of other research firms also recently weighed in on VOR. Barclays reduced their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an "overweight" rating on the stock in a report on Wednesday, August 14th. Robert W. Baird lowered their price objective on Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating for the company in a research note on Friday. Finally, JMP Securities reissued a "market outperform" rating and set a $12.00 target price on shares of Vor Biopharma in a research report on Friday, September 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $11.36.
Get Our Latest Stock Analysis on VOR
Vor Biopharma Stock Performance
VOR traded up $0.12 during trading on Friday, reaching $0.96. 781,468 shares of the company traded hands, compared to its average volume of 504,849. The company has a market cap of $65.53 million, a P/E ratio of -0.48 and a beta of -0.40. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $3.14. The firm has a fifty day simple moving average of $0.80 and a 200 day simple moving average of $1.08.
Vor Biopharma (NYSE:VOR - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). As a group, sell-side analysts expect that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.
Institutional Trading of Vor Biopharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC raised its stake in shares of Vor Biopharma by 48.0% during the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company's stock valued at $495,000 after acquiring an additional 160,642 shares in the last quarter. Rosalind Advisors Inc. bought a new position in shares of Vor Biopharma during the 3rd quarter worth $54,000. Vanguard Group Inc. increased its stake in shares of Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company's stock valued at $4,297,000 after buying an additional 69,436 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vor Biopharma in the second quarter valued at about $63,000. Finally, Acadian Asset Management LLC purchased a new stake in Vor Biopharma in the first quarter worth about $126,000. Hedge funds and other institutional investors own 97.29% of the company's stock.
About Vor Biopharma
(
Get Free Report)
Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Read More
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
